Europe Lung Cancer Diagnostics Market - Industry Trends and Forecast to 2030

Description

List of Tables

The Europe lung cancer diagnostics market is projected to register a substantial CAGR of 13.3% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030

Market Segmentation:

Europe Lung Cancer Diagnostics Market, By Product Type (Instruments, Consumables & Accessories), Test Type (Biomarkers Test, Imaging Test, Biopsy, Blood Test, and Others), Cancer Type (Non-Small Cell Lung Cancer, Small Cell Lung Cancer), End User (Hospital, Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, and Others), Distribution Channel (Direct Tender, Retail Sales), Country (Germany, France, U.K, Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, Rest of Europe) Industry Trends and Forecast to 2030.

Some of the major factors contributing to the growth of the Europe lung cancer diagnostics market are:

Rise in market players and the availability of advanced services

Increase in awareness about the lung cancer diagnostics

Market Players:

Some of the major players operating in the Europe lung cancer diagnostics market are:

F. Hoffmann-La Roche Ltd.

Thermo Fisher Scientific Inc.

Abbott

Quest Diagnostics Incorporated

Bio-Rad Laboratories, Inc.

Biocartis

Danaher

DiaSorin S.p.A.

Exact Sciences UK, Ltd. (a subsidiary of Exact Science Corporation)

Inivata Ltd.

Myriad Genetics, Inc.

NeoGenomics Laboratories

PerkinElmer Inc.

Vela Diagnostics

QIAGEN

Siemens Healthcare GmbH

Veracyte, Inc.

1 INTRODUCTION 28

1.1 OBJECTIVES OF THE STUDY 28
1.2 MARKET DEFINITION 28
1.3 OVERVIEW OF EUROPE LUNG CANCER DIAGNOSTICS MARKET 28
1.4 LIMITATIONS 30
1.5 MARKETS COVERED 30

2 MARKET SEGMENTATION 33

2.1 MARKETS COVERED 33
2.2 GEOGRAPHICAL SCOPE 34
2.3 YEARS CONSIDERED FOR THE STUDY 35
2.4 CURRENCY AND PRICING 35
2.5 DBMR TRIPOD DATA VALIDATION MODEL 36
2.6 MULTIVARIATE MODELLING 39
2.7 PRODUCT TYPE LIFELINE CURVE 39
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 41
2.9 DBMR MARKET POSITION GRID 42
2.10 MARKET TESTING TYPE COVERAGE GRID 44
2.11 VENDOR SHARE ANALYSIS 45
2.12 SECONDARY SOURCES 46
2.13 ASSUMPTIONS 46

3 EXECUTIVE SUMMARY 47

4 PREMIUM INSIGHTS 50

4.1 PORTER'S FIVE FORCES 51
4.2 PESTEL ANALYSIS 52
4.3 INDUSTRY INSIGHTS 53

5 EPIDERMIOLOGY 54

6 REGULATIONS 55

7 MARKET OVERVIEW 58

7.1 DRIVERS 60
- 7.1.1 UNMET NEED FOR NON-INVASIVE, ACCURATE, AND RELIABLE DIAGNOSTIC TESTS FOR EARLIER CANCER DETECTION 60
- 7.1.2 INCREASING EARLY DIAGNOSIS OF LUNGS CANCER 61
- 7.1.3 INCREASING CASES OF LUNG CANCER 63
- 7.1.4 RISE IN PRODUCT APPROVALS 63
7.2 RESTRAINTS 65
- 7.2.1 POOR & LATE DIAGNOSIS OF LUNG CANCER 65
- 7.2.2 HIGH FALSE-POSITIVES AND POOR SENSITIVITY 65
7.3 OPPORTUNITIES 67
- 7.3.1 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT 67
- 7.3.2 GOVERNMENT INITIATIVES TOWARD CANCER DIAGNOSTICS 67
- 7.3.3 RISING AWARENESS OF LUNG CANCER 68
7.4 CHALLENGES 69
- 7.4.1 STRINGENT REGULATORY FRAMEWORK FOR THE APPROVAL AND COMMERCIALIZATION OF CANCER DIAGNOSTIC PRODUCTS 69
- 7.4.2 INCREASED COST, SAFETY, AND CONVENIENCE ISSUES 69
- 7.4.3 LACK OF SKILLED AND CERTIFIED PROFESSIONALS 70

8 EUROPE LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE 71

8.1 OVERVIEW 72
8.2 INSTRUMENTS 75
- 8.2.1 IMAGING INSTRUMENTS 76
  - 8.2.1.1 CT SYSTEMS 76
  - 8.2.1.2 ULTRASOUND SYSTEMS 76
  - 8.2.1.3 MRI SYSTEMS 76
  - 8.2.1.4 OTHERS 76
- 8.2.2 BIOPSY INSTRUMENTS 77
  - 8.2.2.1 NEEDLE BIOPSY 77
  - 8.2.2.2 ENDOSCOPIC BIOPSY 77
  - 8.2.2.3 CORE BIOPSY 77
  - 8.2.2.4 OTHERS 77
- 8.2.3 PATHOLOGY-BASED INSTRUMENTS 78
  - 8.2.3.1 SLIDE STAINING SYSTEMS 78
  - 8.2.3.2 TISSUE PROCESSING SYSTEMS 78
  - 8.2.3.3 CELL PROCESSORS 78
  - 8.2.3.4 PCR INSTRUMENTS 78
  - 8.2.3.5 OTHERS PATHOLOGY-BASED INSTRUMENTS 78
8.3 CONSUMABLES AND ACCESSORIES 79
- 8.3.1 KITS 80
  - 8.3.1.1 DNA POLYMERASE KITS 80
  - 8.3.1.2 NUCLEIC ACID ISOLATION KITS 80
  - 8.3.1.3 PCR KITS 80
  - 8.3.1.4 OTHERS 80
- 8.3.2 REAGENTS 81
  - 8.3.2.1 ASSAYS 81
  - 8.3.2.2 BUFFERS 81
  - 8.3.2.3 PRIMERS 81
  - 8.3.2.4 OTHERS 81
- 8.3.3 PROBES 82
- 8.3.4 OTHER CONSUMABLES 82

9 EUROPE LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE 83

9.1 OVERVIEW 84
9.2 IMAGING TEST 87
- 9.2.1 COMPUTED TOMOGRAPHY (CT) SCAN 88
- 9.2.2 POSITRON EMISSION TOMOGRAPHY (PET) SCAN 88
- 9.2.3 CHEST X-RAY 88
- 9.2.4 BONE SCAN 88
- 9.2.5 MRI 88
- 9.2.6 OTHERS 88
9.3 BIOMARKERS TEST 89
- 9.3.1 EGFR MUTATION TEST 90
- 9.3.2 KRAS MUTATION TEST 90
- 9.3.3 ALK TEST 90
- 9.3.4 HER2 TEST 90
- 9.3.5 OTHERS 91
9.4 BIOPSY 91
- 9.4.1 NEEDLE BIOPSY 92
- 9.4.2 BRONCHOSCOPY BIOPSY 92
- 9.4.3 CORE BIOPSY 92
- 9.4.4 OTHERS 92
9.5 BLOOD TEST 92
- 9.5.1 COMPLETE BLOOD COUNT (CBC) 93
- 9.5.2 BLOOD CHEMISTRY TESTS 93
- 9.5.3 OTHERS 93
9.6 OTHERS 94

10 EUROPE LUNG CANCER DIAGNOSTICS MARKET, BY CANCER TYPE 95

10.1 OVERVIEW 96
10.2 NON-SMALL CELL LUNG CANCER 99
10.3 SMALL CELL LUNG CANCER 100

11 EUROPE LUNG CANCER DIAGNOSTICS MARKET, BY END USER 101

11.1 OVERVIEW 102
11.2 HOSPITAL 105
11.3 ASSOCIATED LABS 105
11.4 INDEPENDENT DIAGNOSTIC LABORATORIES 106
11.5 DIAGNOSTIC IMAGING CENTERS 107
11.6 CANCER RESEARCH INSTITUTES 107
11.7 OTHERS 108

12 EUROPE LUNG CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 109

12.1 OVERVIEW 110
12.2 DIRECT TENDER 113
12.3 RETAIL SALES 114

13 EUROPE LUNG CANCER DIAGNOSTICS MARKET, BY REGION 115

13.1 EUROPE 116
- 13.1.1 GERMANY 126
- 13.1.2 U.K. 131
- 13.1.3 FRANCE 136
- 13.1.4 ITALY 141
- 13.1.5 SPAIN 146
- 13.1.6 RUSSIA 151
- 13.1.7 NETHERLANDS 156
- 13.1.8 SWITZERLAND 161
- 13.1.9 TURKEY 166
- 13.1.10 BELGIUM 171
- 13.1.11 POLAND 176
- 13.1.12 DENMARK 181
- 13.1.13 SWEDEN 186
- 13.1.14 NORWAY 191
- 13.1.15 FINLAND 196
- 13.1.16 REST OF EUROPE 201

14 EUROPE LUNG CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE 202

14.1 COMPANY SHARE ANALYSIS: EUROPE 202

15 SWOT ANALYSIS 203

16 COMPANY PROFILE 204

16.1 F. HOFFMANN-LA ROCHE LTD. (2022) 204
- 16.1.1 COMPANY SNAPSHOT 204
- 16.1.2 REVENUE ANALYSIS 204
- 16.1.3 COMPANY SHARE ANALYSIS 205
- 16.1.4 PRODUCT PORTFOLIO 205
- 16.1.5 RECENT DEVELOPMENTS 205
16.2 THERMO FISHER SCIENTIFIC INC. (2022) 206
- 16.2.1 COMPANY SNAPSHOT 206
- 16.2.2 REVENUE ANALYSIS 206
- 16.2.3 COMPANY SHARE ANALYSIS 207
- 16.2.4 PRODUCT PORTFOLIO 207
- 16.2.5 RECENT DEVELOPMENTS 207
16.3 ABBOTT (2022) 208
- 16.3.1 COMPANY SNAPSHOT 208
- 16.3.2 REVENUE ANALYSIS 208
- 16.3.3 COMPANY SHARE ANALYSIS 209
- 16.3.4 PRODUCT PORTFOLIO 209
- 16.3.5 RECENT DEVELOPMENTS 209
16.4 QUEST DIAGNOSTICS INCORPORATED (2022) 210
- 16.4.1 COMPANY SNAPSHOT 210
- 16.4.2 REVENUE ANALYSIS 210
- 16.4.3 COMPANY SHARE ANALYSIS 211
- 16.4.4 PRODUCT PORTFOLIO 211
- 16.4.5 RECENT DEVELOPMENTS 213
16.5 BIODESIX (2022) 214
- 16.5.1 COMPANY PROFILE 214
- 16.5.2 REVENUE ANALYSIS 214
- 16.5.3 COMPANY SHARE ANALYSIS 215
- 16.5.4 PRODUCT PORTFOLIO 215
- 16.5.5 RECENT DEVELOPMENTS 215
16.6 AMOY DIAGNOSTICS CO., LTD. (2022) 216
- 16.6.1 COMPANY SNAPSHOT 216
- 16.6.2 PRODUCT PORTFOLIO 216
- 16.6.3 RECENT DEVELOPMENTS 216
16.7 BIO-RAD LABORATORIES, INC. (2022) 217
- 16.7.1 COMPANY SNAPSHOT 217
- 16.7.2 REVENUE ANALYSIS 217
- 16.7.3 PRODUCT PORTFOLIO 218
- 16.7.4 RECENT DEVELOPMENTS 218
16.8 BIOCARTIS (2022) 219
- 16.8.1 COMPANY SNAPSHOT 219
- 16.8.2 REVENUE ANALYSIS 219
- 16.8.3 PRODUCT PORTFOLIO 220
- 16.8.4 RECENT DEVELOPMENTS 220
16.9 BODITECH MED INC. 221
- 16.9.1 COMPANY PROFILE 221
- 16.9.2 PRODUCT PORTFOLIO 221
- 16.9.3 RECENT DEVELOPMENTS 221
16.10 DANAHER (2022) 222
- 16.10.1 COMPANY SNAPSHOT 222
- 16.10.2 REVENUE ANALYSIS 222
- 16.10.3 PRODUCT PORTFOLIO 223
- 16.10.4 RECENT DEVELOPMENTS 223
16.11 DIASORIN S.P.A. (2022) 224
- 16.11.1 COMPANY SNAPSHOT 224
- 16.11.2 REVENUE ANALYSIS 224
- 16.11.3 PRODUCT PORTFOLIO 225
- 16.11.4 RECENT DEVELOPMENTS 225
16.12 EXACT SCIENCES UK, LTD. (SUBSIDIARY OF EXACT SCIENCE CORPORATION) (2022) 226
- 16.12.1 COMPANY SNAPSHOT 226
- 16.12.2 REVENUE ANALYSIS 226
- 16.12.3 PRODUCT PORTFOLIO 227
- 16.12.4 RECENT DEVELOPMENTS 227
16.13 20/20 GENE SYSTEMS 228
- 16.13.1 COMPANY PROFILE 228
- 16.13.2 PRODUCT PORTFOLIO 228
- 16.13.3 RECENT DEVELOPMENTS 228
16.14 GUARDANT HEALTH INC. 229
- 16.14.1 COMPANY PROFILE 229
- 16.14.2 PRODUCT PORTFOLIO 229
- 16.14.3 RECENT DEVELOPMENTS 229
16.15 INIVATA LTD. 230
- 16.15.1 COMPANY PROFILE 230
- 16.15.2 PRODUCT PORTFOLIO 230
- 16.15.3 RECENT DEVELOPMENTS 230
16.16 LALPATHLABS.COM (2022) 231
- 16.16.1 COMPANY SNAPSHOT 231
- 16.16.2 REVENUE ANALYSIS 231
- 16.16.3 PRODUCT PORTFOLIO 232
- 16.16.4 RECENT DEVELOPMENTS 233
16.17 LUNGLIFE AI, INC. (2022) 234
- 16.17.1 COMPANY SNAPSHOT 234
- 16.17.2 PRODUCT PORTFOLIO 234
- 16.17.3 RECENT DEVELOPMENTS 234
16.18 MEDGENOME 235
- 16.18.1 COMPANY SNAPSHOT 235
- 16.18.2 PRODUCT PORTFOLIO 235
- 16.18.3 RECENT DEVELOPMENTS 236
16.19 MYRIAD GENETICS, INC. 237
- 16.19.1 COMPANY SNAPSHOT 237
- 16.19.2 PRODUCT PORTFOLIO 237
- 16.19.3 RECENT DEVELOPMENTS 237
16.20 NEOGENOMICS LABORATORIES (2022) 238
- 16.20.1 COMPANY SNAPSHOT 238
- 16.20.2 REVENUE ANALYSIS 238
- 16.20.3 PRODUCT PORTFOLIO 239
- 16.20.4 RECENT DEVELOPMENTS 239
16.21 NANOSTRING (2022) 240
- 16.21.1 COMPANY SNAPSHOT 240
- 16.21.2 REVENUE ANALYSIS 240
- 16.21.3 PRODUCT PORTFOLIO 241
- 16.21.4 RECENT DEVELOPMENTS 241
16.22 NANOENTEK 242
- 16.22.1 COMPANY PROFILE 242
- 16.22.2 PRODUCT PORTFOLIO 242
- 16.22.3 RECENT DEVELOPMENTS 242
16.23 ONCOCYTE CORPORATION 243
- 16.23.1 COMPANY PROFILE 243
- 16.23.2 SERVICE PORTFOLIO 243
- 16.23.3 RECENT DEVELOPMENTS 243
16.24 PERKINELMER INC 244
- 16.24.1 COMPANY PROFILE 244
- 16.24.2 REVENUE ANALYSIS 244
- 16.24.3 PRODUCT PORTFOLIO 245

16.25 PLEXBIO 246
- 16.25.1 COMPANY SNAPSHOT 246
- 16.25.2 PRODUCT PORTFOLIO 246
- 16.25.3 RECENT DEVELOPMENTS 246
16.26 QIAGEN 247
- 16.26.1 COMPANY SNAPSHOT 247
- 16.26.2 REVENUE ANALYSIS 247
- 16.26.3 PRODUCT PORTFOLIO 248
- 16.26.4 RECENT DEVELOPMENTS 248
16.27 SIEMENS HEALTHCARE GMBH 249
- 16.27.1 COMPANY SNAPSHOT 249
- 16.27.2 REVENUE ANALYSIS 249
- 16.27.3 PRODUCT PORTFOLIO 250
- 16.27.4 RECENT DEVELOPMENTS 250
16.28 VERACYTE, INC. (2022) 251
- 16.28.1 COMPANY SNAPSHOT 251
- 16.28.2 REVENUE ANALYSIS 251
- 16.28.3 PRODUCT PORTFOLIO 252
- 16.28.4 RECENT DEVELOPMENTS 252
16.29 VELA DIAGNOSTICS 253
- 16.29.1 COMPANY PROFILE 253
- 16.29.2 PRODUCT PORTFOLIO 253
- 16.29.3 RECENT DEVELOPMENTS 255

17 QUESTIONNAIRE 256

18 RELATED REPORTS 259

LIST OF FIGURES

FIGURE 1 EUROPE LUNG CANCER DIAGNOSTICS MARKET: SEGMENTATION 33
FIGURE 2 EUROPE LUNG CANCER DIAGNOSTICS MARKET: DATA TRIANGULATION 36
FIGURE 3 EUROPE LUNGS CANCER DIAGNOSTICS MARKET: DROC ANALYSIS 37
FIGURE 4 EUROPE LUNG CANCER DIAGNOSTICS MARKET: EUROPE VS REGIONAL MARKET ANALYSIS 38
FIGURE 5 EUROPE LUNG CANCER DIAGNOSTIC MARKET: COMPANY RESEARCH ANALYSIS 38
FIGURE 6 EUROPE LUNG CANCER DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS 41
FIGURE 7 EUROPE LUNG CANCER DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID 42
FIGURE 8 EUROPE LUNG CANCER DIAGNOSTICS MARKET: MARKET END USER COVERAGE GRID 44
FIGURE 9 EUROPE LUNG CANCER DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS 45
FIGURE 10 EUROPE LUNG CANCER DIAGNOSTICS MARKET: SEGMENTATION 49
FIGURE 11 THE INCREASE IN THE AWARENESS ABOUT LUNG CANCER IS EXPECTED TO DRIVE THE EUROPE LUNG CANCER DIAGNOSTICS MARKET IN THE FORECAST PERIOD 50
FIGURE 12 INSTRUMENTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE LUNG CANCER DIAGNOSTICS MARKET IN 2023 & 2030 50
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE EUROPE LUNG CANCER DIAGNOSTICS MARKET 59
FIGURE 14 THE EUROPE MORTALITY RATE DUE TO CANCER 62
FIGURE 15 THE DATA GIVEN BELOW SHOWS THE INCREASING EUROPE CANCER RATE IN 2020 62
FIGURE 16 BARRIERS TO EARLY CANCER DIAGNOSIS AND TREATMENT 65
FIGURE 17 EUROPE LUNG CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2022 72
FIGURE 18 EUROPE LUNG CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2023-2030 (USD MILLION) 73
FIGURE 19 EUROPE LUNG CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, CAGR (2023-2030) 73
FIGURE 20 EUROPE LUNG CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, LIFELINE CURVE 74
FIGURE 21 EUROPE LUNG CANCER DIAGNOSTICS MARKET: BY TEST TYPE, 2022 84
FIGURE 22 EUROPE LUNG CANCER DIAGNOSTICS MARKET: BY TEST TYPE, 2023-2030 (USD MILLION) 85
FIGURE 23 EUROPE LUNG CANCER DIAGNOSTICS MARKET: BY TEST TYPE, CAGR (2023-2030) 85
FIGURE 24 EUROPE LUNG CANCER DIAGNOSTICS MARKET: BY TEST TYPE, LIFELINE CURVE 86
FIGURE 25 EUROPE LUNG CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, 2022 96
FIGURE 26 EUROPE LUNG CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, 2023-2030 (USD MILLION) 97
FIGURE 27 EUROPE LUNG CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, CAGR (2023-2030) 97
FIGURE 28 EUROPE LUNG CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, LIFELINE CURVE 98
FIGURE 29 EUROPE LUNG CANCER DIAGNOSTICS MARKET: BY END USER, 2022 102
FIGURE 30 EUROPE LUNG CANCER DIAGNOSTICS MARKET: BY END USER, 2023-2030 (USD MILLION) 103
FIGURE 31 EUROPE LUNG CANCER DIAGNOSTICS MARKET: BY END USER, CAGR (2023-2030) 103
FIGURE 32 EUROPE LUNG CANCER DIAGNOSTICS MARKET: BY END USER, LIFELINE CURVE 104
FIGURE 33 EUROPE LUNG CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2022 110
FIGURE 34 EUROPE LUNG CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION) 111
FIGURE 35 EUROPE LUNG CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030) 111
FIGURE 36 EUROPE LUNG CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 112
FIGURE 37 EUROPE LUNG CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022) 117
FIGURE 38 EUROPE LUNG CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022) 118
FIGURE 39 EUROPE LUNG CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 118
FIGURE 40 EUROPE LUNG CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030) 119
FIGURE 41 EUROPE LUNG CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE (2023-2030) 119
FIGURE 42 EUROPE LUNG CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%) 202